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Abstract
Background: The nonhuman primate model of glaucomatous optic neuropathy most faithfully
reproduces the human disease. We used high-density oligonucleotide arrays to investigate whole
genome transcriptional changes occurring at the optic nerve head during primate experimental
glaucoma.
Results:  Laser scarification of the trabecular meshwork of cynomolgus macaques produced
elevated intraocular pressure that was monitored over time and led to varying degrees of damage
in different samples. The macaques were examined clinically before enucleation and the myelinated
optic nerves were processed post-mortem to determine the degree of neuronal loss. Global gene
expression was examined in dissected optic nerve heads with Affymetrix GeneChip microarrays.
We validated a subset of differentially expressed genes using qRT-PCR, immunohistochemistry, and
immuno-enriched astrocytes from healthy and glaucomatous human donors. These genes have
previously defined roles in axonal outgrowth, immune response, cell motility, neuroprotection, and
extracellular matrix remodeling.
Conclusion: Our findings show that glaucoma is associated with increased expression of genes
that mediate axonal outgrowth, immune response, cell motility, neuroprotection, and ECM
remodeling. These studies also reveal that, as glaucoma progresses, retinal ganglion cell axons may
make a regenerative attempt to restore lost nerve cell contact.
Background
The glaucomas are a multifactorial group of diseases with
many different causes and one common endpoint: the
loss of retinal ganglion cells of the retina, leading to thin-
ning of the retinal nerve fiber layer and deficits in the vis-
ual field [1-3]. Ocular hypertension is the leading risk
factor for glaucoma [4,5]. For human patients presenting
with glaucoma, treatments that lower intraocular pressure
are effective, even in cases where intraocular pressure is
not abnormally elevated [6]. In animal models, interven-
tions that produce elevated intraocular pressure lead to
predictable retinal ganglion cell loss [7,8].
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Astrocytes are the most abundant glial cells in the adult
central nervous system. Normally, astrocytes provide met-
abolic and structural support to neurons and participate
in the maintenance and detoxification of the extracellular
space of the central nervous system. In neurodegenerative
diseases or following central nervous system injury, quies-
cent astrocytes acquire a reactive phenotype and produce
many enzymes, proteins, cytokines, and free radicals that
are not produced under normal conditions [9,10].
As part of the change from quiescent astrocytes to reactive
astrocytes, glaucomatous optic nerve head astrocytes
exhibit differential expression of a large number of genes
[11]. Reactive astrocytes in glaucomatous eyes may ini-
tially represent a cellular attempt to limit the extent of
neuronal injury and to promote tissue repair, but reactive
glial cells may also have noxious effects on optic nerve
axons by creating mechanical injury and/or changing the
microenvironment of neurons [12-14]. Previous studies
from our laboratory reported that genes related to lipid
synthesis and metabolism, steroid metabolism and glu-
tathione metabolism were upregulated in optic nerve
head astrocytes cultured from patients with primary open
angle glaucoma [11,15,16]. In addition, reactive astro-
cytes in the glaucomatous optic nerve head engage in
extracellular matrix (ECM) remodeling of the lamina cri-
brosa [12] leading to the cupping or excavation of the
optic disc characteristic of glaucoma [17].
Our working model of damage in ocular hypertensive
glaucoma states that abnormally elevated intraocular
pressure converts normal optic nerve head astrocytes to
"reactive" astrocytes, which are characterized by the
increased expression of glial fibrillary acidic protein
(GFAP) [10,18,19], a member of the intermediate fila-
ment family uniquely expressed by astrocytes and consid-
ered to be a hallmark of central nervous system injury
[20]. There is evidence that elevated hydrostatic pressure
can directly trigger astrocytes to assume the reactive phe-
notype [18,21,22].
Several recent studies have used whole genome microar-
rays to catalog changes in transcription that accompany
glaucoma. These have included the analysis of primary
cultures of human optic nerve head astrocytes from glau-
comatous donors [11]; cultured human optic nerve head
astrocytes from normal donors exposed to pressure for
varying periods of time [23]; optic nerve head cells from a
rat model of glaucoma [24]; and the retinal cells of several
animal models of glaucoma, including the DBA/2J mouse
[25], the cynomolgus macaque [26], and the rat [27].
There are substantial transcriptional differences between
cells in vivo and in vitro [28-30]. Due to the unique anat-
omy and sophistication of the primate lamina cribrosa,
nonhuman primate models are preferred for glaucoma
research and replicate the disease with the highest fidelity
[7,8]. This is because the nonhuman primate visual sys-
tem, including the structure of the optic nerve head, is
nearly identical to that of human [31,32]. This contrasts
with mice, which do not have a lamina cribrosa, and rats,
which have a very primitive lamina cribrosa [33,34]. The
primate model develops visual field deficits and cupping
that are indistinguishable from those in human glaucoma
[1,35]. For the present study, we used a nonhuman pri-
mate model to investigate transcriptional changes in the
cells of the optic nerve head during experimental glau-
coma. High-density oligonucleotide microarrays identi-
fied global transcriptional changes in the nonhuman
primate optic nerve head. We then compared these find-
ings to the genes that are altered in immuno-enriched cul-
tures of optic nerve head astrocytes from glaucomatous
human donors.
Results
Elevation of intraocular pressure
Intraocular pressure readings from Goldmann applana-
tion tonometry are shown in Figure 1 from the first read-
ing above 25 mm Hg in each laser treated eye. Table 1 and
Table 2 show physiological data for all samples processed
for microarray.
Table 1: Control and ExpG cynomolgus macaques.
Macaque Age (years) Sex Axon loss (%) Evaluation Control/ExpG
577 6 F 21 Mild Paired
578 6 F 25 Mild Paired
579 6 F 32 Mild Paired
566 7 F 74 Advanced Paired
529 5 1/2 M 59 Moderate Paired
K605os 5 M 0 Control Control
K605od 5 M 0 Control Control
590os 4 F 0 Control Control
All samples used for microarray and qRT-PCR in the present study. 'Axon loss' and 'Evaluation' are as defined in Methods. M = male; F = female.BMC Neuroscience 2008, 9:93 http://www.biomedcentral.com/1471-2202/9/93
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Evaluation of damage
Fundus photographs are shown for samples 577 (21%
axon loss), 578 (25% axon loss), and 566 (74% axon
loss) [see Additional file 1]. These samples gave a repre-
sentative picture of the progression of glaucomatous
enlargement of the rim of the optic nerve head and thin-
ning of the retinal nerve fiber layer.
Further  in vivo evaluation of retinal nerve fiber layer
(RNFL) thickness was made with the GDx VCC scanning
laser polarimetry (SLP) with variable corneal compensa-
tion [see Additional file 2]. SLP is an ocular imaging tech-
nique based on the birefringence of the RNFL, and has
been used to obtain reproducible quantitative measure-
ments of the RNFL in human and monkey eyes [60]. The
GDx VCC has a variable corneal polarization compensa-
tor (VCC) that allows for individual eye birefringence
compensation, which increases the accuracy of the RNFL
thickness assessment. GDxVCC images are color coded for
thickness. Darker colors (e.g. blue) represent thinner areas
of RNFL and bright colors (e.g. orange) represent thicker
areas. Differences in SLP parameters between the experi-
mental glaucoma (ExpG) eyes and healthy control eyes of
the samples were assessed to quantify RNFL damage.
Thinning in the typical glaucomatous, "hourglass" shape
[61] was evident, with images showing more pronounced
change from orange to blue coloration in the superior and
inferior regions.
To further quantify disease progression, axon loss was
measured from cross-sections of the optic nerve of each
sample processed for microarray analysis (Table 2).
Remapping of probe set definitions to Affymetrix human 
microarrays
Recent improvements in sequencing and genomic analy-
sis have led to more accurate "definitions" that relate oli-
gonucleotide sequences on the Affymetrix arrays to
expressed RNAs [46]. We used these more accurate defini-
tions (intended for human and chimpanzee) to update
the probe sets of the Affymetrix HGU133A and
HGU133Av2 oligonucleotide microarrays used in this
study. Limited genomic information is available for the
cynomolgus macaque, the species used for this study.
However, the close evolutionary relationship of humans
and chimpanzees to the macaque permits microarray
analysis using human chips and gene definitions from
either humans or chimpanzees. Because the cynomolgus
macaque is evolutionarily approximately equidistant
from humans and chimpanzees, there is theoretically no
advantage in using either the human or the chimpanzee
definitions for the analysis of transcripts from the
macaque. We performed the microarray analysis in dupli-
cate, using definitions for both human and chimpanzee.
The Affymetrix detection call algorithm reliably elimi-
nates probe sets that, due to sequence variations between
species, do not hybridize accurately [56]. It was used to
eliminate false hybridization signals (see Methods). As
our most compelling targets were verified using qRT-PCR,
any candidates generated with either of the two sets of def-
initions could be verified with this more precise tech-
nique. Using human UniGene-based definitions, 4,357
probesets were detected in 16/33 arrays, and 4,358
probesets were detected in 14/28 arrays (for all five ExpG
eyes compared to eight control eyes); using chimpanzee
UniGene-based definitions, 3,844 probesets were
detected in 16/33 arrays, and 3,842 probesets were
detected in 14/28 arrays (for three mild ExpG eyes com-
pared to eight control eyes).
Results of statistical testing
When comparing microarray data from the five ExpG eyes
with the control group of eight eyes, the UniGene-based
chimpanzee definitions identified 30 significant, differen-
tially expressed probe sets, and the UniGene-based
human definitions produced 33 significant, differentially
expressed probe sets (Table 3). Nineteen significant, dif-
ferentially expressed probe sets were shared between the
two groups. Human definitions identified guanine nucle-
otide-binding protein, gamma-transducing activity
polypeptide 1 (GNGT1), which was likely introduced as a
retina-specific contaminant during the dissection [62].
Table 2: Clinical data for ExpG cynomolgus macaques.
Macaque IOP, control 
eye (mm Hg)
IOP, ExpG eye 
(mm Hg)
Duration 
elevated IOP 
(weeks/days)
C/D ratio 
control eye
C/D ratio ExpG 
eye
Axon loss (%) Evaluation
577 15.0 ± 2.6 24.7 ± 7.5 10.9/76 0.25 0.4 21 Mild
578 17.1 ± 2.4 33.2 ± 10.3 33.4/234 0.25 0.5 25 Mild
579 19.1 ± 1.8 28.1 ± 4.5 12.6/88 0.4 0.7 32 Mild
566 15.0 ± 2.7 27.4 ± 18.5 6.1/43 0.25 0.8 74 Advanced
529 13.8 ± 2.3 36.0 ± 18.5 7.3/51 0.2 0.9 59 Moderate
Experimental paired cynomolgus macaques used for the microarray analysis and qRT-PCR verification of the present study.
IOP measurements represent mean ± SD. 'Axon loss' and 'Evaluation' are as defined in Methods.
IOP = Intraocular pressure. C/D ratio = cup/disk ratio. M = male; F = female.BMC Neuroscience 2008, 9:93 http://www.biomedcentral.com/1471-2202/9/93
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Chimpanzee definitions identified phosducin (PDC),
also likely a retina-specific contaminant [63]. For this rea-
son, GNGT1 and PDC were removed from further consid-
eration. Fold change (i.e. fold increase or fold decrease)
and standard error of fold change were nearly identical for
transcripts identified using both definitions.
The same analysis was performed after omitting the two
most advanced glaucoma samples (529, 566) to identify
differentially expressed probe sets that were preferentially
expressed during the mild stages of experimental glau-
coma (Table 4).
Prediction of cell types expressing differentially expressed 
genes
We were most interested in genes differentially expressed
by optic nerve head astrocytes and retinal ganglion cells
during experimental glaucoma. To estimate which genes
Intraocular pressure measurements for five paired glaucomatous samples Figure 1
Intraocular pressure measurements for five paired glaucomatous samples. Intraocular pressure measurements from 
day of first laser in ExpG eye to sacrifice. Day 0 (vertical line) is the first time intraocular pressure was above 25 mm Hg.BMC Neuroscience 2008, 9:93 http://www.biomedcentral.com/1471-2202/9/93
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Table 3: Significant differentially expressed probesets from five ExpG eyes compared to eight control eyes by microarray.
PROBESET Definition Group fold 
change
Representativ
e public ID
Gene title Gene 
symbol
RP SAM ONH 
astrocyte
RGC
Hs.103291 HS, PT 1.79 ± 0.68 NM_016588 neuritin 1 NRN1 0.00 0.01 NA Y
Hs.12333 HS, PT -1.69 ± 0.25 NM_007282 ring finger protein 13 RNF13 0.03 0.01 Y NA
Hs.134974 HS, PT 1.70 ± 0.37 NM_002045 growth associated protein 43 GAP43 0.06 0.01 N Y
Hs.155097 HS, PT -1.62 ± 0.49 M36532 carbonic anhydrase II CA2 0.05 0.11 N NA
Hs.155247 HS -2.37 ± 0.94 NM_005165 aldolase C, fructose-
bisphosphate
ALDOC 0.00 0.01 Y Y
Hs.165636 HS, PT 1.88 ± 0.54 NM_017594 DIRAS family, GTP-binding 
RAS-like 2
DIRAS2 0.00 0.00 NA NA
Hs.198760 HS 8.37 ± 4.66 X15306 neurofilament, heavy 
polypeptide 200 kDa
NEFH 0.00 0.00 N Y
Hs.233240 HS, PT 1.66 ± 0.60 NM_004369 collagen, type VI, alpha 3 COL6A3 0.03 0.11 Y NA
Hs.235873 HS, PT -1.61 ± 0.48 NM_024897 progestin and adipoQ 
receptor family member VI
PAQR6 0.01 0.08 NA NA
Hs.277035 HS 1.48 ± 0.20 BC006230 monoglyceride lipase MGLL 0.31 0.01 Y NA
Hs.308709 HS -2.22 ± 0.88 NM_005313 protein disulfide isomerase, 
family A, member 3
PDIA3 0.03 0.15 Y NA
Hs.351279 HS, PT 1.90 ± 0.56 X76775 major histocompatibility 
complex, class II, DM alpha
HLA-DMA 0.02 0.01 N NA
Hs.369397 HS, PT 1.63 ± 0.32 NM_000358 transforming growth factor, 
beta-induced, 68 kDa
TGFBI 0.05 0.00 Y NA
Hs.378901 HS, PT -1.49 ± 0.30 NM_014717 zinc finger protein 536 ZNF536 0.06 0.03 N NA
Hs.412355 HS 1.82 ± 0.83 NM_001492 growth differentiation factor 
1/LAG1 homolog, ceramide 
synthase 1
GDF1/LASS1 0.01 0.08 Y NA
Hs.435557 HS, PT -1.75 ± 0.39 BF059313 kinesin family member 5C KIF5C 0.02 0.00 N NA
Hs.443625 HS, PT 2.01 ± 0.63 NM_000090 collagen, type III, alpha 1 
(Ehlers-Danlos syndrome 
type IV, autosomal dominant)
COL3A1 0.01 0.01 Y NA
Hs.458573 HS, PT 1.47 ± 0.20 NM_006207 platelet-derived growth 
factor receptor-like
PDGFRL 0.15 0.00 Y NA
Hs.478153 HS, PT -1.62 ± 0.45 NM_005025 serpin peptidase inhibitor, 
clade I (neuroserpin), 
member 1
SERPINI1 0.03 0.14 Y Y
Hs.483444 HS 1.60 ± 0.49 AF144103 chemokine (C-X-C motif) 
ligand 14
CXCL14 0.03 0.07 NA NA
Hs.485130 HS 1.79 ± 0.52 NM_002121 major histocompatibility 
complex, class II, DP beta 1
HLA-DPB1 0.03 0.02 Y NA
Hs.489142 HS, PT 1.62 ± 0.42 NM_000089 collagen, type I, alpha 2 COL1A2 0.03 0.01 Y NA
Hs.48924 HS -1.85 ± 0.46 NM_014782 armadillo repeat containing, 
X-linked 2
ARMCX2 0.03 0.03 Y NA
Hs.496622 HS, PT -1.80 ± 0.41 NM_005032 plastin 3 
(T isoform)
PLS3 0.03 0.03 Y NA
Hs.515354 HS -1.73 ± 0.58 NM_002361 myelin-associated 
glycoprotein
MAG 0.05 0.23 Y NA
Hs.515369 HS 1.77 ± 0.55 NM_003332 TYRO protein tyrosine 
kinase binding protein
TYROBP 0.03 0.14 N NA
Hs.518525 HS -1.60 ± 0.30 NM_002065 glutamate-ammonia ligase 
(glutamine synthetase)
GLUL 0.07 0.00 Y NA
Hs.520048 HS 1.50 ± 0.56 M60333 major histocompatibility 
complex, class II, DR alpha
HLA-DRA 0.03 0.51 Y NA
Hs.529571 HS, PT 1.63 ± 0.44 NM_002899 retinol binding protein 1, 
cellular
RBP1 0.02 0.03 Y Y
Hs.550276 HS, PT 1.59 ± 0.23 NA NA NA 0.07 0.00 Y NA
Hs.70327 HS 1.68 ± 0.38 NM_001311 cysteine-rich protein 1 
(intestinal)
CRIP1 0.03 0.01 Y NA
Hs.88778 HS, PT -1.90 ± 0.44 BC002511 carbonyl reductase 1 CBR1 0.03 0.01 Y NA
Hs.109225 PT 1.58 ± 1.42 NM_001078 vascular cell adhesion 
molecule 1
VCAM1 0.04 0.48 Y NA
Hs.144197 PT -1.74 ± 0.50 NM_003360 UDP glycosyltransferase 8 
(UDP-galactose ceramide 
galactosyltransferase)
UGT8 0.02 0.06 N NABMC Neuroscience 2008, 9:93 http://www.biomedcentral.com/1471-2202/9/93
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Hs.190495 PT 6.78 ± 4.64 NM_002510 glycoprotein 
(transmembrane) nmb
GPNMB 0.00 0.01 Y Y
Hs.388664 PT 1.53 ± 0.50 NM_000975 ribosomal protein L11 RPL11 0.03 0.47 Y NA
Hs.502235 PT 2.30 ± 1.03 NA NA NA 0.01 0.02 Y Y
Hs.518773 PT -2.22 ± 0.58 BF448062 ubiquitin-conjugating enzyme 
E2D 3 
(UBC4/5 homolog, yeast)
UBE2D3 0.04 0.01 Y NA
Hs.530902 PT 1.63 ± 0.42 NM_005849 immunoglobulin superfamily, 
member 6
IGSF6 0.10 0.02 N NA
Hs.532768 PT 1.60 ± 0.39 NM_002615 pigment epithelium derived 
factor/serpin peptidase 
inhibitor, clade F, member 1
PEDF/
SERPINF1
0.13 0.02 Y NA
Hs.58414 PT 1.69 ± 0.63 NM_001458 filamin C, gamma 
(actin binding protein 280)
FLNC 0.04 0.09 Y NA
Hs.75285 PT 1.49 ± 0.39 NM_002216 inter-alpha (globulin) 
inhibitor H2
ITIH2 0.05 0.03 N NA
'Definition' indicates the species definitions used; 'HS' indicates human; 'PT' indicates chimpanzee. For transcripts identified by both definitions (e.g. 
NRN1), the data shown in the table was produced using the human definition. Fold change (i.e. fold increase or fold decrease) and standard error of 
fold change were calculated as described in Methods. 'RP' indicates p-values generated by Rank Products; 'SAM' indicates p-values generated by 
significance analysis of microarrays. 'ONH Astrocyte' and 'RGC' indicate probable expression in optic nerve head astrocytes and retinal ganglion 
cells, respectively (Methods); 'NA' indicates no data were available.
Table 3: Significant differentially expressed probesets from five ExpG eyes compared to eight control eyes by microarray. (Continued)
Table 4: Significant differentially expressed probesets from three mild ExpG eyes compared to eight control eyes by microarray.
PROBESET Definition Group Fold 
Change
Representative 
Public ID
Gene Title Gene Symbol RP SAM ONH 
Astrocyte
RGC
Hs.103291 HS, PT 2.19 ± 0.87 NM_016588 neuritin 1 NRN1 0.03 0.07 NA Y
Hs.165636 HS, PT 2.21 ± 0.65 NM_017594 DIRAS family, 
GTP-binding RAS-
like 2
DIRAS2 0.02 0.01 NA NA
Hs.198760 HS, PT 4.67 ± 2.47 X15306 neurofilament, 
heavy polypeptide 
200 kDa
NEFH 0.02 0.20 N Y
Hs.369397 HS, PT 1.86 ± 0.46 NM_000358 transforming 
growth factor, 
beta-induced, 68 
kDa
TGFBI 0.11 0.05 Y NA
Hs.515369 HS 1.63 ± 0.23 NM_003332 TYRO protein 
tyrosine kinase 
binding protein
TYROBP 0.20 0.01 N NA
Hs.529571 HS, PT 1.94 ± 0.48 NM_002899 retinol binding 
protein 1, cellular
RBP1 0.08 0.02 Y Y
Hs.75318 HS, PT 1.57 ± 0.20 AL565074 tubulin, alpha 4a TUBA4A 0.20 0.02 Y NA
Hs.211914 PT 1.65 ± 0.22 BC005954 NADH 
dehydrogenase 
(ubiquinone) Fe-S 
protein 7, 20 kDa 
(NADH-coenzyme 
Q reductase)
NDUFS7 0.23 0.01 Y NA
Hs.512610 PT 1.76 ± 0.36 NM_016199 LSM7 homolog, U6 
small nuclear RNA 
associated 
(S. cerevisiae)
LSM7 0.15 0.02 Y NA
This comparison was performed to preferentially identify transcripts that changed during the mild stages of glaucomatous axonal damage. Samples 
577, 578, and 579 had axonal losses ranging from 25%–32% (Table 2) and were tested separately. Results are shown here. Samples 566 and 529 
had more severe axonal loss (74% and 59%, respectively; Table 2) and were excluded from this comparison. 'Definition' indicates the species 
definitions used; 'HS' indicates human; 'PT' indicates chimpanzee. For transcripts identified by both definitions (e.g. NRN1), the data shown in the 
table were produced using the human definition. Fold change (i.e. fold increase or fold decrease) and standard error of fold change were calculated 
as described in Methods. 'RP' indicates indicates p-values generated by Rank Products; 'SAM' indicates indicates p-values generated by significance 
analysis of microarrays. 'ONH Astrocyte' and 'RGC' indicate probable expression in optic nerve head astrocytes and retinal ganglion cells, 
respectively (see Methods); 'NA' indicates no data were available.BMC Neuroscience 2008, 9:93 http://www.biomedcentral.com/1471-2202/9/93
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were expressed by optic nerve head astrocytes, detection
call information from previously published Affymetrix
datasets from this laboratory was used [11,23]. Retinal
ganglion cell expression data from one EST and one
microarray study was obtained, respectively, from [58]
and [59]. Both microarray tables include columns with
optic nerve head astrocyte and retinal ganglion cell expres-
sion data for the significant transcripts (Table 3, Table 4).
Validation of selected differentially expressed genes by 
real-time RT-PCR
Transcripts selected from Table 3 (GAP43, GPNMB,
NEFH), Table 4 (NEFH), or the results of individual
paired comparisons (APOE, BMP2, CAPG, NEFL, STMN2)
[see Additional file 3] were confirmed by quantitative real
time PCR in the two most mild (577, 578) and two most
advanced (566, 529) experimental, paired samples.
Results are shown in Table 5 as relative gene expression
values (fold change) between the laser-treated eye and the
normal contralateral eye. There was good correlation
between the quantitative real time PCR data and the
microarray results. Primer sequences are provided [see
Additional file 4].
Histological confirmation of selected genes
To further investigate genes identified by microarray, laser
treated cynomolgus and rhesus macaque samples with
mild to moderate axon loss [see Additional file 5 and
Additional file 6] were processed for immunohistochem-
istry with antibodies to growth-associated protein 43
(GAP43), glycoprotein transmembrane non-metastatic B
(GPNMB), and neurofilament heavy (NEFH). GPNMB
was chosen because it is a null mutation in the DBA/2J
mouse strain, which develops iris pigment dispersion syn-
drome and iris stromal atrophy; the former was mapped
to a premature stop mutation in GPNMB [64,65]; NEFH
and GAP43 were chosen because they are markers of
axonal regrowth [66,67], which has not been previously
described in a primate glaucoma model.
Two NEFH antibodies were used to examine the localiza-
tion of upregulated NEFH in the axons of optic nerves of
healthy and experimental glaucoma monkeys. NEFH
immunohistochemistry with an antibody that recognizes
phosphorylated and non-phosphorylated NEFH shows
axons in the normal sample traversing through the lamina
cribrosa in well-organized bundles (Figure 2A), while the
axons in ExpG were disorganized with an abnormal
axonal morphology (Figure 2B). Staining with an anti-
body that recognizes predominantly phosphorylated
NEFH revealed presumptive growth cone-like structures
in the post laminar optic nerves of monkeys with experi-
mental glaucoma, which also were positive for GAP43
(Figure 2C), whereas these structures were absent in con-
trol monkeys. Optic nerve astrocytes expressed abundant
GAP-43 in ExpG. Stathmin+ oligodendrocyte processes
encircled the axonal bulbs in ExpG (Figure 2D). The
growth cone-like structures were observed in all ExpG
optic nerves examined. Double staining with NEFH and
protein disulfide isomerase (PDI), a marker of endoplas-
mic reticulum vesicles, suggested new protein synthesis in
axons [68] and glial cells in the optic nerve (Figure 2E, F).
GPNMB immunohistochemistry is shown in Figure 3. In
control samples, GPNMB protein was detected in the reti-
nal ganglion cell and nerve fiber layers of the retina (Fig-
Table 5: qRT-PCR verification of selected transcripts in ExpG.
Transcript 577 FX 578 FX 566 FX 529 FX
APOE qRT-PCR 1.11 ± 0.13 1.15 ± 0.16 3.55 ± 0.38 3.07 ± 0.38
Microarray 1.75 ± 0.24 -1.15 ± 0.15 2.95 ± 0.52 1.24 ± 0.16
BMP2 qRT-PCR 1.92 ± 0.13 -1.29 ± 0.19 3.30 ± 0.16 3.25 ± 0.35
Microarray 1.34 ± 0.06 -1.30 ± 0.12 2.19 ± 0.36 2.14 ± 0.56
CAPG qRT-PCR 1.26 ± 0.09 1.72 ± 0.25 5.70 ± 0.35 1.66 ± 0.16
Microarray 1.54 ± 0.20 1.05 ± 0.09 3.93 ± 0.36 -1.13 ± 0.15
GAP43 qRT-PCR 2.49 ± 0.15 1.39 ± 0.24 3.32 ± 0.33 3.18 ± 0.50
Microarray 1.52 ± 0.07 -1.04 ± 0.04 2.83 ± 0.26 1.55 ± 0.21
GPNMB qRT-PCR 2.40 ± 0.15 3.17 ± 0.31 90.68 ± 9.07 3.77 ± 0.27
Microarray 1.68 ± 0.26 1.27 ± 0.28 29.64 ± 6.44 2.04 ± 0.50
NEFH qRT-PCR 1.74 ± 0.24 4.86 ± 0.35 1.65 ± 0.14 56.48 ± 6.53
Microarray 2.95 ± 0.21 6.18 ± 0.85 2.53 ± 0.26 42.68 ± 4.88
NEFL qRT-PCR 2.46 ± 0.14 7.75 ± 0.37 -1.63 ± 0.13 5.38 ± 0.97
Microarray 2.22 ± 0.14 3.59 ± 0.21 1.15 ± 0.06 1.71 ± 0.29
STMN2 qRT-PCR 2.44 ± 0.10 13.12 ± 0.95 -1.04 ± 0.07 4.03 ± 0.33
Microarray 1.69 ± 0.11 3.46 ± 0.32 -1.04 ± 0.06 1.77 ± 0.36
qRT-PCR verification in four paired glaucomatous macaques of eight selected transcripts. Fold change (i.e. fold increase or fold decrease; 'FX') was 
calculated within each paired sample as described in Methods. Standard error of fold change was calculated as described in Methods.
Numerical values for microarray are from human definitions, with the exception of GPNMB, which was not detected by human definitions.BMC Neuroscience 2008, 9:93 http://www.biomedcentral.com/1471-2202/9/93
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Axonal morphology of monkey optic nerves with experimental glaucoma in sagittal sections of the ONH (Macaque #2; Supple- mental Table 3) Figure 2
Axonal morphology of monkey optic nerves with experimental glaucoma in sagittal sections of the ONH 
(Macaque #2; Supplemental Table 3). (A) Sagittal view of the normal optic nerve head stained for neurofilament heavy 
(red, NF200). Superimposed in blue is the DIC image of the structure of the lamina cribrosa (LC). (B) Similar view of the con-
tralateral ExpG eye. Note irregular size and morphology of the axons (arrows) in the optic nerve head in experimental glau-
coma (A and B, scale bar, 50 μm). NB = nerve bundles. (C) Co-localization of GAP43 (green) and phosphorylated NEFH (red) 
in bulb-like structures (Ax) in ExpG. Astrocytes (arrows) in the pial septa (PS) show abundant GAP43 staining. NB = nerve 
bundle (scale bar, 25 μm). (D) Double immunostaining for stathmin (red) and phosphorylated neurofilament (green) shows oli-
godendrocyte processes (arrows) on axonal bulb-like structures (Ax) in ExpG. PS = pial septa (scale bar, 25 μm). (E) Co-local-
ization of protein disulfide isomerase (PDI), a marker of endoplasmic reticulum, and phosphorylated NEFH (SMI31) in some 
axons in the nerve bundles (NB) in normal post laminar optic nerve suggested the presence of ribosomes, seen as green gran-
ules within axons. Notice that glial cells in the pial septa (PS) (arrowheads) stain positive for PDI (scale bar, 40 μm) (F). PDI and 
phosphorylated NEFH co-localization in axons in nerve bundles (NB) in ExpG (arrows). Abnormal axon (Ax) stained with 
NEFH and PDI in ExpG optic nerve (scale bar, 25 μm). Nuclei are stained with DAPI.BMC Neuroscience 2008, 9:93 http://www.biomedcentral.com/1471-2202/9/93
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Expression of GPNMB in experimental glaucoma in sagittal sections of the ONH (Macaque #3; Supplemental Table 3) Figure 3
Expression of GPNMB in experimental glaucoma in sagittal sections of the ONH (Macaque #3; Supplemental 
Table 3). (A) Low expression of GPNMB (red) in the retinal ganglion cell layer (GCL) and nerve fiber layer (NFL) in control 
monkey eye. Granular staining of GPNMB is present in the area adjacent to the inner limiting membrane (ILM). Very low stain-
ing for GFAP (green) is observed in the normal nerve fiber layer. Nuclei are stained with DAPI. (B) Upregulation of GPNMB in 
retinal ganglion cells (GCL) and in axons and retinal astrocytes in the nerve fiber layer in ExpG. Notice marked increase in 
GFAP staining in the nerve fiber layer. A, B: Magnification bar = 25 μm. (C) Low expression of GPMNB in astrocytes and axons 
in the normal monkey optic nerve head. (D) Marked upregulation of GPNMB in axons in the nerve bundles (NB) and in GFAP+ 
astrocytes (green) in the lamina cribrosa (LC) and glial columns (GC). Note that GPNMB appears to localize to the nucleus and 
cytoplasm in astrocytes in ExpG. C, D: Magnification bar = 40 μm. (E and F) Low expression of GPNMB associated with 
astrocytes and axons in the post laminar optic nerve. (E, Control; F, ExpG). E, F: Magnification bar = 40 μm.BMC Neuroscience 2008, 9:93 http://www.biomedcentral.com/1471-2202/9/93
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ure 3A). In ExpG samples, GPNMB protein was sharply
upregulated in retinal ganglion cells and their axons, and
in retinal astrocytes in the retinal nerve fiber layer (Figure
3B). Within the optic nerve head, healthy samples had
baseline expression levels of GPNMB protein in astrocytes
and retinal ganglion cell axons (Figure 3C). In ExpG sam-
ples, GPNMB was sharply upregulated in retinal ganglion
cells and their axons, as well as optic nerve head astrocytes
(Figure 3D). GPNMB staining appeared to localize to the
membranes of GFAP+ astrocytes. In contrast, GFAP+
astrocytes in the lamina cribrosa exhibited strong GPNMB
staining where, at higher magnification, GPNMB protein
could be seen around and over the nucleus in ExpG.
Abundant GPNMB was also present in axons in the nerve
bundles at the level of the lamina cribrosa (Figure 3D).
Low levels of GPNMB were present in astrocytes, oli-
godendrocytes and nerve fibers in the myelinated post
laminar optic nerve in normal and in ExpG (Figure 3E, F)
Labeling with stathmin (STMN) antibody revealed spe-
cific upregulation of STMN in ExpG. Within the retina,
STMN immunoreactivity was very low in normal eyes
(Figure 4A). In ExpG, STMN was detected in the nerve
fiber layer and in few GFAP-negative process-bearing cells.
Retinal ganglion cells and retinal astrocytes did not
exhibit STMN immunoreactivity (Figure 4B). In the prela-
minar optic nerve head, low levels of STMN were
expressed in the glial columns and in the nerve bundles in
both control and ExpG samples without obvious differ-
ences (Figure 4C, D). In both control and ExpG, STMN
expression was absent from the lamina cribrosa and
present in the optic nerve proper. Oligodendrocytes
exhibited strong immunoreactivity for STMN in the
somata and cell processes (Figure 4E, F). In ExpG, many
oligodendrocytes exhibited bipolar shape with long proc-
esses (Figure 4F). In control eyes STMN stained the nerve
bundles, but not in ExpG (Figure 4E, F). Positive staining
with adenomatous polyposis coli (APC) identified these
cells as oligodendrocytes (inset, Figure 4F). STMN was not
expressed in GFAP+ astrocytes in the myelinated nerve.
These results were consistent amongst all the samples, as
were the negative controls for specificity of the primary
and secondary antibodies. Staining in cynomolgus ONH
was not different from the rhesus ONH samples.
Confirmation of the expression of selected genes in human 
optic nerve head astrocytes
qRT-PCR was used to examine the expression of GPNMB,
RBP1, CAPG, APOE, TGFBI, and TIMP1, which were iden-
tified in the nonhuman primate model, in immuno-
enriched optic nerve head astrocytes from glaucomatous
Caucasian American donors [see Additional file 7 and
Additional file 8]. Figure 5 shows qRT-PCR confirmation
of differential expression of the five genes in immuno-
enriched optic nerve head astrocytes from healthy and
glaucomatous human donors. CAPG, GPNMB, RBP1,
APOE and TIMP1 were significantly upregulated in astro-
cytes from glaucomatous donors, consistent with their
upregulation in the tissues of the macaque optic nerve
head with ExpG. TGFBI was upregulated significantly by
microarray (Table 3, Table 4), but not by qRT-PCR (Fig
5F). Two genes, NEFH and GPNMB, exhibited higher fold
increases in samples with moderate to advanced glau-
coma. In sample 566, GPNMB variation may be due to
infiltration of the ONH with microglia or macrophages, as
has been previously reported in advanced glaucoma in
humans [69]. The higher NEFH increase in sample 529
may be due to retinal contamination or to higher IOP
exposure in that spontaneous glaucoma compared to the
laser treated samples.
Discussion
We used the nonhuman primate model of glaucoma to
investigate transcriptional changes occurring at the optic
nerve head, the region thought to be the primary site of
damage to retinal ganglion cells in glaucoma [70-73]. We
validated selected transcripts with qRT-PCR, which gener-
ally agreed with microarray in direction and, to a lesser
degree, magnitude. Our data was consistent with others'
observations that larger fold changes in Affymetrix chips,
with updated definitions [46], correlated best with qRT-
PCR [55]. In addition, we used human optic nerve head
astrocytes from normal and glaucomatous human donors
to demonstrate independent upregulation of five putative
astrocyte genes selected from the microarray data in mon-
keys with experimental glaucoma.
Previous studies have shown that updated sequence defi-
nitions for Affymetrix GeneChips produced improved
estimates of differential expression [46,74-78]. In the
present study, updated definitions produced more
'present' transcripts by the detection call algorithm
[56,57] (data not shown), indicating that more hybrid-
ized transcripts were accurately detected.
Significant differentially expressed transcripts could be
divided into five categories, and some have putative or
established roles in multiple categories. Axonal elonga-
tion and synaptic plasticity genes, including growth-asso-
ciated protein 43 (GAP43), neurofilament heavy (NEFH),
and neuritin 1 (NRN1), preferentially expressed by retinal
ganglion cells, indicated an attempt to re-extend lost or
damaged axons. There was an upregulation of neuropro-
tective genes, including apolipoprotein E (APOE), cellular
retinol binding protein 1 (RBP1), and pigment epithe-
lium derived factor (PEDF/SERPINF1). We confirmed the
upregulation of RBP1 in immuno-enriched optic nerve
head astrocytes from glaucomatous human donors. This
suggested that optic nerve head astrocytes attempted toBMC Neuroscience 2008, 9:93 http://www.biomedcentral.com/1471-2202/9/93
Page 11 of 21
(page number not for citation purposes)
Stathmin protein expression in experimental glaucoma in sagittal sections of the ONH (Macaque #5; Supplemental Table 3) Figure 4
Stathmin protein expression in experimental glaucoma in sagittal sections of the ONH (Macaque #5; Supple-
mental Table 3). (A) Stathmin (red) is not expressed in the retinal ganglion cell layer (GCL) or in the retinal nerve fiber layer 
(NFL) in the retina of normal monkeys. GFAP stains retinal astrocytes (green). (B) In ExpG, stathmin staining is present in the 
nerve fiber layer presumably in axons. Stathmin does not co-localize with GFAP+ retinal astrocytes in the nerve fiber layer. 
Some cells bearing processes stain strongly for stathmin in the nerve fiber layer (arrows). Magnification bar: A = 25 μm; B = 40 
μm. (C, D) Co-localization of stathmin and GFAP in astrocytes of the glial columns (GC) in the optic nerve head in normal 
optic nerve head and ExpG. Axons in the nerve bundles (NB) also exhibit staining for stathmin. Note that cells in the lamina 
cribrosa (LC) are devoid of staining for stathmin. Magnification bar = 55 μm. (E) Stathmin stains oligodendrocytes in the post-
laminar optic nerve in normal optic nerves. (F) Stathmin-labeled bipolar oligodendrocytes (arrows) are abundant in the post-
laminar optic nerve in ExpG. Insert shows co-localization of APC (green), a marker of oligodendrocytes cell bodies and non-
myelinating processes with stathmin in the post laminar optic nerve. Magnification bar = 35 μm.BMC Neuroscience 2008, 9:93 http://www.biomedcentral.com/1471-2202/9/93
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Real time quantitative RT-PCR from human donor ONH astrocytes Figure 5
Real time quantitative RT-PCR from human donor ONH astrocytes. qRT-PCR was performed using mRNA isolated 
from primary cultures of ONH astrocytes derived from nine donors with primary open angle glaucoma (CAG) and nine age-
matched Caucasian American normal donors (CA; Supplemental Table 2). Clear bars indicate control samples (CA) and 
filled-in bars indicate glaucomatous samples (CAG). Values represent the mean ± SE of relative expression normalized to 18S 
of each group of normal and glaucomatous astrocytes. For each donor, reactions were carried out in triplicate. A. GPNMB, 
fold change = 16.81; p = 0.0004. B. RBP1, fold change = 6.02; p = 0.02. C. CAPG fold change = 2.55; p = 0.02. D. TIMP1, fold 
change = 1.77; p = 0.02. E. APOE, fold change = 17.91; p = 0.04. F. TGFBI, fold change = 1.58; p > 0.05.BMC Neuroscience 2008, 9:93 http://www.biomedcentral.com/1471-2202/9/93
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facilitate retinal ganglion cell axon outgrowth by upregu-
lation of neuroprotective molecules. Differential expres-
sion of motility genes, including capping protein G
(CAPG) and transforming growth factor beta-induced
(TGFBI), was consistent with the reactive, migratory astro-
cyte phenotype characteristic of glaucoma [12], as were
ECM remodeling genes, such as GPNMB [79,80] and
TIMP1 [81,82]. Immune genes, such as TYRO protein
tyrosine kinase binding protein (TYROBP), major histo-
compatibility complex class II DM alpha (HLA-DMA),
major histocompatibility complex class II DP beta 1
(HLA-DPB1), and major histocompatibility complex class
II DR alpha (HLA-DRA), were likely expressed by infiltrat-
ing mononuclear cells, resident microglia, macrophages,
and possibly also astrocytes acting as non-professional
antigen-presenting cells [83-86]. The most compelling
candidates for investigation are discussed further below in
the context of glaucoma.
The appearance of GAP43+ and phospho-NEFH+ growth
cone-like structures in the optic nerve has not been previ-
ously reported in the nonhuman primate model or in
human glaucoma. It is thought that primate retinal gan-
glion cells do not regenerate damaged axons in vivo,
including in glaucoma [87]. However, axon regeneration,
accompanied by new protein synthesis in axons, was
reported in dorsal root ganglia [88]. Our finding suggests
that there may be plasticity in the adult primate optic
nerve and possibly a window period, early in hypertensive
glaucoma, when retinal ganglion cell axons attempt to
regenerate. If true, this would underscore the importance
of early diagnosis and early treatment of glaucoma, as
post-mortem histological studies have shown that up to
half of retinal ganglion cells are typically lost in glaucoma
before any visual field defects are present. Alternatively,
these structures may represent retraction bulbs that are
characteristic of the disorganized microtubule network of
damaged axons [89]. Future experiments will distinguish
between these possibilities.
Capping protein G (CAPG) is a member of the gelsolin-
villin family, and modulates cellular motility by capping
actin filaments [90]. The importance of astrocyte motility
in the progression of glaucoma is a present focus of inves-
tigation [24]; the upregulation of CAPG in the experimen-
tal glaucoma samples as well as in immuno-enriched
optic nerve head astrocytes from Caucasian American
donors with glaucoma makes it a strong candidate as an
astrocyte migratory gene in glaucoma. Further, increased
expression of capping protein G (CAPG) was shown pre-
viously by microarray and Western blot in purified
human optic nerve head astrocytes from glaucomatous
donors [11]. There is evidence that CAPG is regulated by
elements of the AP-1 transcription factor complex [91],
which was activated in the primate model of glaucoma
[18]. CAPG has been shown to promote matrix metallo-
proteinase (MMP) activity [92]. The MMPs are a family of
powerful ECM degrading enzymes [93] that may facilitate
optic nerve head excavation in glaucoma [81,82,94].
GPNMB is a 560 amino acid, type I transmembrane glyc-
oprotein. In the present study, GPNMB was sharply upreg-
ulated in optic nerve head astrocytes of Caucasian
American donors with glaucoma. Roles have been
ascribed to GPNMB in the immune system [95,96], in
stress responses [97], and in ECM remodeling [79,80].
The latter has been underscored by roles for GPNMB in
tumor invasion [98,99], where GPNMB promoted inva-
siveness through MMPs and also induced activation of
epidermal growth factor receptor (EGFR) [80]. EGFR acti-
vation is characteristic of reactive astrocytes [9,100] and
has been shown in glaucoma [13,101].
The DBA/2J mouse develops pigmentary glaucoma from
the release of pigment and degenerated cellular compo-
nents of the iris pigment epithelium and stroma that alter
drainage structures, elevating intraocular pressure [102].
Two distinct eye diseases produce glaucoma in the DBA/
2J strain – iris pigment dispersion syndrome, which was
mapped to a null mutation in GPNMB, and iris stromal
atrophy, which was mapped to a mutation in TYRP1
[64,65]. DBA/2J mice with wild type GPNMB develop
very mild iris disease with no retinal ganglion cell loss
[103]. The DBA/2J has immune system defects [104,105]
and immune roles for GPNMB in glaucoma must be
investigated further, as GPNMB can function as a feedback
regulator of macrophage activation [95]. The upregula-
tion of GPNMB in the primate model and in optic nerve
head astrocytes from glaucomatous human donors sug-
gests that proper immune function of astrocytes, as non-
professional antigen presenting cells, may require
GPNMB. Possible immune roles for GPNMB in optic
nerve head astrocytes should be examined.
Conclusion
We have identified a small group of genes differentially
expressed in the optic nerve head of primates with experi-
mental hypertensive glaucoma. Most have no previously
characterized roles in glaucoma, yet many have previously
identified roles elsewhere that suggest roles in glaucoma.
Our most novel finding is that in mild glaucoma, before
the appearance of visual field defects, retinal ganglion cell
axons may make a regenerative attempt. The upregulation
of neuroprotective genes in the glaucomatous optic nerve
head supports this. Further investigations should deter-
mine whether neuroprotective molecules identified here
can increase retinal ganglion cell survival in animal mod-
els of glaucoma.BMC Neuroscience 2008, 9:93 http://www.biomedcentral.com/1471-2202/9/93
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Methods
Animals
Four cynomolgus macaques (Macaca fascicularis) had uni-
lateral experimental ocular hypertension (4 experimental
eyes and 4 control eyes), one macaque had unilateral
"spontaneous" ocular hypertension, and 2 macaques had
normal intraocular pressure and were used as controls.
Data for the samples is presented in Table 1 and Table 2.
Animal model of ocular hypertension
Unilateral laser scarification of the trabecular meshwork
[37,38] was performed in 4 female cynomolgus macaques
with a standard, clinical argon laser, or green diode laser
and slit lamp delivery system. This was used to place 50 to
250 spots, 50 or 75 μm in diameter (1.0–1.5 W of energy;
0.5 to 0.8-second duration), over approximately 270° of
the angle circumference while leaving one quadrant
untreated. If increased intraocular pressure was not
achieved, laser surgery was repeated at 3- to 4-week inter-
vals, after ocular inflammation subsided. Anesthesia for
laser surgery and fundus photography was induced with
injections of intramuscular (i.m.) ketamine hydrochlo-
ride (10 mg/kg), supplemented with injections of i.m.
medetomidine (15–75 μg/kg). A fifth macaque, sample
529, was used in two experiments that involved cannulat-
ing the anterior chamber, 1 and 2 years prior to develop-
ing elevated intraocular pressure. This macaque is referred
to as the spontaneous glaucoma sample, as it is unclear as
to whether either of these events were causes of the
intraocular pressure elevation.
Under ketamine anesthesia, intraocular pressure was
monitored with a minified Goldmann applanation
tonometer [39] (Haag-Streit, Koniz, Switzerland), as well
as a handheld applanation tonometer (Tono-pen XL;
Mentor O & O, Norwell, Mass) if head or eye movements
made accurate Goldmann readings impossible. The
untreated, contralateral eye served as a normal control.
Stereoscopic fundus photography was used to determine
optic nerve cupping before and after laser treatment as
well as before sacrifice.
For sacrifice, anesthesia was induced with i.m. ketamine
(10 mg/kg), followed by deep pentobarbital anesthesia
(15 mg/kg intravenous (i.v.)). All macaque work was per-
formed under the guidelines of the ARVO Statement for
the Use of Animals in Ophthalmic and Vision Research.
GDx VCC scanning laser polarimetry
Monkeys were anesthetized with a combination of i.m.
ketamine and medetomidine, followed by isoflurane, an
inhalation anesthetic agent. Monkeys were maintained at,
or near, surgical anesthetic depth for the scanning proce-
dure using the GDx VCC (Zeiss, Dublin, CA). A 10 mm
plano contact lens was applied to ensure adequate corneal
hydration. Corneal birefringence compensation was cal-
culated at baseline and verified by 3 or more compensated
macular scans at each time point. During each session, 3
to 5 separate peripapillary scans were taken and the mean
was calculated. The scan head was realigned between
scans to generate discrete images. Definitions of the indi-
vidual parameters and the technology of the instrument
are described elsewhere [40-43].
Tissue collection
Following sacrifice, the posterior segment of each eye was
placed into RNALater (Ambion) and kept at 4°C until dis-
section was performed. The optic nerve head was carefully
dissected from the eye and under the dissecting micro-
scope, the sclera, meningeal sheaths and all traces of pig-
mented cells were removed. The resulting cylinder was
then bisected with a sharp sterile blade and the border of
myelinated nerve was visualized. A cut was made to
include a sliver of approximately 1 mm of the myelinated
nerve from the samples. Total RNA was isolated in TRIzol
(Invitrogen Life Technologies, Carlsbad, CA), and tissue
was minced in TRIzol with a scalpel blade. On average 1.5
μg of RNA was isolated per sample. After isolation, RNA
was precipitated and resuspended in 10 μl nuclease-free
water. RNA quality was verified by processing 250ng of
RNA by capillary electrophoresis. RNA quantity and
purity was estimated by measuring absorbance at 260 nm
and absorbance ratios at 260/280 nm.
Evaluation of nerve damage
To evaluate optic nerve damage, cross sections were taken
from myelinated optic nerves fixed in 4% paraformalde-
hyde, osmicated, embedded in plastic and stained with p-
phenylenediamine (PDA). After PDA, degenerated axons
stain in dark brownish-red color whereas normal axons
appear as black circles with a clear center due to staining
of myelin. Digital images were taken at 2× magnification,
so that the entire cross-sectional area of the nerve was
within the lens field. Images were imported into Optimas
software (Bothel, WA), for measurement of total circum-
ference area and areas with axonal degeneration. The area
occupied by degenerated axons was measured and
expressed as the percentage of the total cross-sectional
area. "Mild" axon loss was defined as a loss of up to a third
(33%) of myelinated axon area, "moderate" axon loss
when there was loss up to two thirds (66%) of myelinated
axon area, and "advanced" axon loss was when the loss in
axon area surpassed 66% of the total myelinated area as in
[44].
Reverse Transcription and Quantitative Real Time PCR
qRT-PCR was performed using 1 μg of total RNA isolated
from the corresponding macaque optic nerve head.BMC Neuroscience 2008, 9:93 http://www.biomedcentral.com/1471-2202/9/93
Page 15 of 21
(page number not for citation purposes)
Reverse transcription, primer design and quantitative real
time PCR were described previously in detail [15]. Primer
sequences are provided [see Additional file 4]. 18S RNA or
RPL19 was used as endogenous control. Fold change (i.e.
fold increase or fold decrease) was calculated within each
individual macaque between paired control and experi-
mental eyes.
Confirmation of selected genes in optic nerve head 
astrocytes from Caucasian American glaucomatous and 
control donors
Cytoplasmic RNA was isolated from cultured optic nerve
head astrocytes (passage 3) from nine different glaucoma
donors and nine different normal donors. The character-
istics of the glaucoma donors are provided [see Additional
file 7 and Additional file 8]. RNA from cultured optic
nerve head astrocytes belonging to one eye of each of the
donors was used. For quantitative real time PCR (qRT-
PCR) conditions and primer sequences see Supplemental
Table 2. For each cell culture, PCR reactions were per-
formed in triplicate. Amplification of 18S ribosomal RNA
was performed in all samples to normalize gene expres-
sion values. The threshold cycle (Ct) values of each sam-
ple and the standards were loaded into Microsoft Excel for
further analysis. The mean and SEM of relative expression
level were calculated for all target genes. Gene expression
levels in all samples were expressed as the ratio of the gene
of interest to 18S expression. Statistical analysis of the
results was done using the statistical functions of the
Graphpad Prism 4.0 software. Significant differences
between the means were set at p < 0.05 (ANOVA followed
by Bonferroni correction). For each target and the corre-
sponding control gene, we used six individual normal and
six glaucomatous donors simultaneously, each donor in
triplicate. This was done to run all samples plus standards
simultaneously in one plate.
Monkey tissues for immunohistochemistry
Ocular tissue from 1 female cynomolgus monkey (aged 5
years) and 3 female and 2 male rhesus monkeys (Macaca
mulatta) (aged 3–5 years), with monocular experimental
glaucoma, were used to detect selected protein gene prod-
ucts in the optic nerve head and retina [see Additional file
5 and Additional file 6] Surgical procedure and tissue
processing were described earlier in detail [45]. The mon-
keys were perfused through the heart with 4% paraformal-
dehyde in 0.1 M phosphate-buffered saline (PBS) pH 7.4,
following deep pentobarbital anesthesia. After enuclea-
tion, the eyes were immersed in 4% paraformaldehyde for
12–24 h and the optic nerve head (with 2–3 mm of mye-
linated nerve) was dissected from surrounding tissues. Tis-
sue was extensively washed in 0.2% glycine in PBS and
processed for paraffin embedding. The retina and optic
nerve were used for immunohistochemistry.
Immunohistochemistry
Immunocytochemistry was performed on 6 μm sagittal
sections of the optic nerve head containing retina and
myelinated nerve. The specificity and optimal dilution of
the antibodies were tested using monkey optic nerve head
tissues. We used rabbit polyclonal antibodies against
stathmin (1:50; Cell Signaling Technology); growth-asso-
ciated protein 43 (GAP43), a marker for axonal growth
(1:200; Santa Cruz Biotechnology); and neurofilament
heavy (NF200) (1:250, Sigma St. Louis, MO). The poly-
clonal anti-NF200 antibody recognizes both phosphor-
ylated and dephosphorylated forms of the 200-kDa
neurofilament. We also used a monoclonal antibody
against phosphorylated neurofilament heavy (1:250;
SMI31, Sternberger Monoclonals, Baltimore, MD) that
reacts only with a phosphorylated epitope in extensively
phosphorylated forms of this polypeptide. We used mon-
oclonal antibodies against GPNMB (1:500; Abnova Cor-
poration, Taiwan) and protein disulfide isomerase (PDI),
a marker of endoplasmic reticulum vesicles (1:200; Stress-
gen Biotechnologies, Canada). To localize selected gene
products to optic nerve and retinal astrocytes, we per-
formed double immunohistochemistry using mono- and
polyclonal antibodies against glial fibrillary acidic protein
(GFAP) (1:400 and 1:200 respectively; Sigma), an astro-
cyte marker. To localize stathmin to oligodendrocytes, we
used a mouse monoclonal antibody against Adenomatus
polyposis coli (APC), a marker for oligodendroglial cells
(1:200; Calbiochem). We used secondary antibodies
Alexa 488 and Alexa 568 (1:400; Molecular Probes,
Eugene, OR). Slides were mounted with Prolong® mount-
ing media containing DAPI for nuclear staining. For neg-
ative controls, the primary antibody was replaced for the
appropriate non-immune serum. To control for cross reac-
tivity in double immunofluorescence, sections were incu-
bated with primary antibody followed by the wrong
species' secondary antibody. Sections of normal and glau-
comatous eyes were stained simultaneously to control for
variations in immunostaining. Slides were examined in a
Nikon Eclipse 80i microscope (Tokyo, Japan) equipped
with epifluorescent illumination and digital cameras
(Photometrics). The images were processed using Meta
Imaging Series software (Molecular Devices) and stored as
computer files.
Oligonucleotide microarray hybridization
For microarray hybridization, cDNA was synthesized
from 50ng of total RNA using the Superscript Choice Sys-
tem (Life Technologies, Gaithersburg, MD) and T7-(dT)
24 primer (GENSET, La Jolla, CA) with an additional step
of linear amplification. Amplicon length was on the order
of 100 bp. In vitro transcription was done with purified
double-stranded cDNA as the template in the presence of
biotinylated UTP and CTP using a Bioassay High Yield
RNA Transcript Labeling Kit (Enzo Diagnostics,BMC Neuroscience 2008, 9:93 http://www.biomedcentral.com/1471-2202/9/93
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Farmingdale, NY). Biotinylated cRNA was purified with
Qiagen RNAeasy cleanup (Qiagen, Valencia, CA).
Hybridization of labeled cRNA to Affymetrix HG-U133A
(cynomolgus macaque 529) and HG-U133Av2 (all other
cynomolgus macaques) chips was done using the Gene-
Chip Instrument System (Affymetrix, Santa Clara, CA) at
the GeneChip Core Facility of Washington University.
Arrays were washed and stained with strepavidin-phyco-
erythrin (Molecular Probes, Eugene, OR). Arrays were
scanned with the Agilent GeneArray Scanner (Agilent
Technologies, Palo Alto, CA). The output Affymetrix .CEL
files were generated and scaled to target intensity 1,500
with the Affymetrix Microarray Suite software package
(version 5.0). The details of each GeneChip used for the
primate model are provided [see Additional file 9].
Bioinformatic and statistical analysis of oligonucleotide 
microarray data
All analyses of microarray .CEL files were done using the
open source statistical package R version 2.7.0 http://
www.r-project.org/[45] and Bioconductor release 2.1
http://bioconductor.org[46]. The complete R script con-
taining our analyses for the control and experimental
glaucoma (ExpG) macaques has been provided [see Addi-
tional File 10], which allows the reader to perform the
identical analysis using provided raw data from the cur-
rent study [see Additional Files 11, 12, 13, 14, 15, 16, 17].
Oligonucleotide microarray normalization
Prior to any low-level or high-level analysis, probe sets on
all chips were first remapped to updated UniGene probe
set definitions (version 6) intended for Homo sapiens and
Pan troglodytes (chimpanzee) downloaded from http://
brainarray.mbni.med.umich.edu/brainarray[46]. After
remapping probe sets to the latest UniGene cluster IDs,
the 'combineAffyBatch' function, from the Bioconductor
'matchprobes' library [47] version 1.8.1, was used to
merge Affymetrix HG-U133A and HG-U133Av2 chips
prior to normalization. All chips were normalized in one
batch with the robust multiarray normalization (RMA)
algorithm [48] using the 'rma' function, from the Biocon-
ductor 'affy' library version 1.17.3 [49], with default set-
tings. Our empirical observations and those of others
working in nonhuman primates [50] determined RMA
normalization to be the most accurate of several tested.
Each biological sample was then scaled to mean zero, var-
iance one using the 'normalize' function in the R 'som'
library version 0.3–4 to minimize technical artifacts prior
to statistical testing. Details of the parameters of these
methods are presented in the R script provided [see Addi-
tional File 10].
Statistical testing of control versus glaucoma groups
R statistical language implementations of Rank Products
(RP) [51] ('RankProd' library version 2.8.0) and Signifi-
cance Analysis of Microarrays (SAM) [52] ('siggenes'
library version 1.12.0) were downloaded from the Bio-
conductor website http://www.bioconductor.org. A sig-
nificance cutoff of p = 0.05 was required to be deemed
significantly differentially expressed. Each individual eye
was used as an independent biological sample. RP and
SAM produce q-values which are simultaneously adjusted
for false discovery rate [53,54]. Details of the parameters
of these methods are presented in the R script provided
[see Additional File 10].
We performed two rounds of statistical testing and ad-hoc
filtering. One was performed to identify genes that
changed across all stages of ExpG, and the next was to
preferentially identify genes that changed in the mild
stages of ExpG. Specifically, we tested for genes that
changed significantly between all eight control eyes and
all five ExpG eyes (Table 3), and also tested for genes that
changed significantly between all eight control eyes and
the three mild ExpG eyes (577, 578, 579; Table 4). The
additional ad-hoc filtering for each round was performed
as described below.
Calculation of fold change
Fold change (i.e. fold increase or fold decrease) was calcu-
lated between experimental and control groups by averag-
ing technical replicates together for each biological
sample, averaging all control biological and all experi-
mental biological samples, and dividing the experimental
mean by the control mean for upregulated probe sets, or
dividing the control mean by the experimental mean and
appending a negative sign for downregulated probe sets.
Standard error of fold change was calculated for group
comparisons using the expression values for each biolog-
ical sample. For individual, paired biological sample cal-
culations, standard error of fold change was calculated
using technical replicate values for the corresponding bio-
logical sample.
Ad-hoc filtering of results of statistical testing by absent/
present calls and fold change for all experimental 
glaucoma eyes versus all control sample eyes
In addition to selection by p-value, we applied an arbi-
trary fold change (i.e. fold increase or fold decrease) cutoff
of 45% between control and ExpG groups. This step was
taken to ensure that truly differentially expressed tran-
scripts were identified; others have noted that larger fold
changes (also by Affymetrix microarray) correlate more
closely with qRT-PCR measurements than smaller
changes [55].BMC Neuroscience 2008, 9:93 http://www.biomedcentral.com/1471-2202/9/93
Page 17 of 21
(page number not for citation purposes)
The next filter we applied was by Affymetrix detection call.
Probe sets called 'present' (p <= 0.05 by Wilcoxon one-
sided signed rank test; [56,57]) with the 'mas5calls' func-
tion from the 'affy' library in approximately half of the
total number of GeneChips (16 out of 33 total chips) were
retained for further analysis. We chose this relatively strin-
gent arbitrary cutoff to ensure that only reliably detected
transcripts would be retained for further investigation.
Finally, we applied an additional fold change filter. We
stipulated that probesets retained for the final list of sig-
nificant differentially expressed genes must also pass a
fold change cutoff of 45% in at least two of the five paired,
experimental samples. This final step was done to ensure
that transcripts that had extreme changes in a single sam-
ple had not biased the calculated group fold changes.
Ad-hoc filtering of results of statistical testing by absent/
present calls and fold change for three mild experimental 
glaucoma eyes versus all control sample eyes
This analysis was performed in the same manner as for the
entire group comparison above, using only the three mild
ExpG samples (577, 578, 579) and excluding the two
advanced ExpG samples (566, 529). As for the entire
group comparison above, all eight control samples were
used. Following statistical testing, probe sets that were
called 'present' in 14 out of 28 chips, changed 45%
between control and mild ExpG groups, and also changed
45% between control and ExpG eyes in at least two of the
three paired mild samples (577, 578, 579) were identified
as significantly differentially expressed between groups.
Prediction of cell types expressing differentially expressed 
transcripts
Two previously published in vitro datasets of immuno-
panned cultures of pure optic nerve head astrocytes were
used for calculation of 'present' probe sets [11] (NCBI
GEO GSE2378); [23] (NCBI GEO GSE758). These data-
sets were remapped to human UniGene-based definitions
(Version 6) [46] and RMA normalized [48] as described
for the macaque data. Probe sets were considered
expressed by optic nerve head astrocytes if called 'present'
in at least 25% of all microarray chips from either [23] or
[11]. These were matched to any significant genes from
the present study on multiple identifiers.
Retinal ganglion cell expression data from EST libraries
and microarray was obtained, respectively, from [58] and
[59], and matched on multiple identifiers. Probe sets were
considered expressed by retinal ganglion cells if detected
in retinal ganglion cells in either of the two studies.
Additional information from the scientific literature was
used to predict cell-type expression and to exclude any
false positives resulting from retinal contamination dur-
ing the dissection.
Abbreviations
ECM: Extracellular (matrix); (ExpG): experimental glau-
coma; (GEO): Gene Expression Omnibus; (GFAP): glial
fibrillary acidic protein; (LC): lamina cribrosa; (ONH):
optic nerve head; (POAG): primary openangle glaucoma;
(PCR): polymerase chain reaction; (qRT-PCR): quantita-
tive real-time PCR; (RP): Rank Products; (RNFL): retinal-
nerve fiber layer; (SAM): Significance Analysis of
Microarrays; (VCC): variable corneal compensation.
Authors' contributions
All animal work was performed by PLK and CAR at the
Department of Ophthalmology & Visual Sciences, Univer-
sity of Wisconsin, Madison. CAR and MRH wrote sections
of the manuscript. MRH designed the study, made figures,
and performed microscopy. OAO performed dissections
and RNA isolation. OAO, KSK, and WL performed qRT-
PCR experiments. KSK performed analysis of array data
and wrote the manuscript. All authors critically read and
revised the manuscript.
Additional material
Additional file 1
kompass_et_al_BMC_Neuroscience. Fundus photography images for 
selected ExpG samples.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2202-9-93-S1.doc]
Additional file 2
kompass_et_al_BMC_Neuroscience. GDx VCC scans for selected ExpG 
samples.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2202-9-93-S2.doc]
Additional file 3
Kompass_et_al_BMC_Neuroscience. Individual stages of microarray 
data processing that generated the results shown in Table 3 and Table 4.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2202-9-93-S3.zip]
Additional file 4
kompass_et_al_BMC_Neuroscience. Primer sequences for quantitative 
real-time PCR.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2202-9-93-S4.doc]
Additional file 5
kompass_et_al_BMC_Neuroscience. Clinical information for macaque 
samples used for immunohistochemistry.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2202-9-93-S5.doc]BMC Neuroscience 2008, 9:93 http://www.biomedcentral.com/1471-2202/9/93
Page 18 of 21
(page number not for citation purposes)
Acknowledgements
We are extremely grateful to Paula Malone, Ping Yang, Mary Feldmeier, 
Lori Worley, Mike Onken, and Rachel Delston for their very generous help 
and kind use of their equipment. David Beebe, William Harbour, Gary 
Stormo, and Jim Cheverud provided helpful comments on the manuscript. 
Belinda McMahon performed expert histology. John Peterson and Beth 
Hennes-Beean provided expert photography and animal handling for these 
studies. We are indebted to four anonymous reviewers whose comments 
greatly improved the quality of the manuscript. This work was supported 
by NIH EY-06416 (MRH), and EY02698 (PLK), Research to Prevent Blind-
ness (MRH, PLK), Ocular Physiology Research and Education Foundation, 
(PLK) and Retina Research Foundation (PLK; Watler H. Helmerich Chair) 
P30 EY016665 (core grant for vision research; PLK).
References
1. Harwerth RS, Quigley HA: Visual field defects and retinal gan-
glion cell losses in patients with glaucoma.  Arch Ophthalmol
2006, 124(6):853-859.
2. Weinreb RN, Shakiba S, Zangwill L: Scanning laser polarimetry to
measure the nerve fiber layer of normal and glaucomatous
eyes.  Am J Ophthalmol 1995, 119(5):627-636.
3. Quigley HA: Number of people with glaucoma worldwide.  Brit-
ish Journal of Ophthalmology 1996, 80(5):389.
4. Armaly MF, Krueger DE, Maunder L, Becker B, Hetherington J Jr,
Kolker AE, Levene RZ, Maumenee AE, Pollack IP, Shaffer RN: Biosta-
tistical analysis of the collaborative glaucoma study. I. Sum-
mary report of the risk factors for glaucomatous visual-field
defects.  Arch Ophthalmol 1980, 98(12):2163-2171.
5. Quigley HA, Enger C, Katz J, Sommer A, Scott R, Gilbert D: Risk fac-
tors for the development of glaucomatous visual field loss in
ocular hypertension.  Archives of Ophthalmology 1994,
112(5):644-649.
6. Weinreb RN, Khaw PT: Primary open-angle glaucoma.  The Lan-
cet 2004, 363(9422):1711-1720.
Additional file 6
kompass_et_al_BMC_Neuroscience. Intraocular pressure measurements, 
for six paired ExpG samples used for immunohistochemistry, from day of 
first laser in ExpG eye to sacrifice. Day 0 (vertical line) is the first time 
intraocular pressure was above 25 mm Hg.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2202-9-93-S6.pdf]
Additional file 7
kompass_et_al_BMC_Neuroscience. Clinical information for control 
Caucasian American donors used to generate primary cultures of ONH 
astrocytes.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2202-9-93-S7.doc]
Additional file 8
kompass_et_al_BMC_Neuroscience. Clinical information for POAG 
Caucasian American donors used to generate primary cultures of ONH 
astrocytes.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2202-9-93-S8.doc]
Additional file 9
kompass_et_al_BMC_Neuroscience. Details of Affymetrix chips used in 
the primate study.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2202-9-93-S1.doc]
Additional file 10
kompass_et_al_BMC_Neuroscience. R statistical language script con-
taining microarray analysis for Table 3 and Table 4. Includes instructions 
for how to install required R and Bioconductor libraries to repeat the anal-
ysis. Script may be pasted into an R session or called using the 'source' 
function in R.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2202-9-93-S10.r]
Additional file 11
kompass_et_al_BMC_Neuroscience. Raw microarray data for sample 
577.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2202-9-93-S11.zip]
Additional file 12
kompass_et_al_BMC_Neuroscience. Raw microarray data for sample 
578.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2202-9-93-S12.zip]
Additional file 13
kompass_et_al_BMC_Neuroscience. Raw microarray data for sample 
579.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2202-9-93-S13.zip]
Additional file 14
kompass_et_al_BMC_Neuroscience. Raw microarray data for sample 
566.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2202-9-93-S14.zip]
Additional file 15
kompass_et_al_BMC_Neuroscience. Raw microarray data for sample 
529.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2202-9-93-S15.zip]
Additional file 16
kompass_et_al_BMC_Neuroscience. Raw microarray data for sample 
k605.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2202-9-93-S16.zip]
Additional file 17
kompass_et_al_BMC_Neuroscience. Raw microarray data for sample 
m590os.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2202-9-93-S17.zip]BMC Neuroscience 2008, 9:93 http://www.biomedcentral.com/1471-2202/9/93
Page 19 of 21
(page number not for citation purposes)
7. Rasmussen CA, Kaufman PL: Primate glaucoma models.  J Glau-
coma 2005, 14(4):311-314.
8. Weinreb RN, Lindsey JD: The importance of models in glau-
coma research.  J Glaucoma 2005, 14(4):302-304.
9. Eddleston M, Mucke L: Molecular profile of reactive astrocytes
– implications for their role in neurologic disease.  Neuro-
science 1993, 54(1):15-36.
10. Ridet JL, Malhotra SK, Privat A, Gage FH: Reactive astrocytes: cel-
lular and molecular cues to biological function.  Trends Neurosci
1997, 20(12):570-577.
11. Hernandez MR, Agapova OA, Yang P, Salvador-Silva M, Ricard CS,
Aoi S: Differential gene expression in astrocytes from human
normal and glaucomatous optic nerve head analyzed by
cDNA microarray.  Glia 2002, 38(1):45-64.
12. Hernandez MR: The optic nerve head in glaucoma: role of
astrocytes in tissue remodeling.  Prog Retin Eye Res 2000,
19(3):297-321.
13. Liu B, Neufeld AH: Activation of epidermal growth factor
receptor signals induction of nitric oxide synthase-2 in
human optic nerve head astrocytes in glaucomatous optic
neuropathy.  Neurobiol Dis 2003, 13(2):109-123.
14. Morgan JE: Optic nerve head structure in glaucoma: astro-
cytes as mediators of axonal damage.  Eye (London 1987) 2000,
14:437-444.
15. Agapova OA, Kaufman PL, Hernandez MR: Androgen receptor
and NFkB expression in human normal and glaucomatous
optic nerve head astrocytes in vitro and in experimental
glaucoma.  Exp Eye Res 2006, 82(6):1053.
16. Malone PE, Hernandez MR: 4-Hydroxynonenal, a product of oxi-
dative stress, leads to an antioxidant response in optic nerve
head astrocytes star, open.  Experimental Eye Research 2007,
84(3):444-454.
17. Quigley HA, Green WR: The histology of human glaucoma cup-
ping and optic nerve damage: clinicopathologic correlation
in 21 eyes.  Ophthalmology 1979, 86(10):1803-1830.
18. Hashimoto K, Parker A, Malone P, Gabelt BT, Rasmussen C, Kaufman
PS, Hernandez MR: Long-term activation of c-Fos and c-Jun in
optic nerve head astrocytes in experimental ocular hyper-
tension in monkeys and after exposure to elevated pressure
in vitro.  Brain Res 2005, 1054(2):103-115.
19. Varela HJ, Hernandez MR: Astrocyte responses in human optic
nerve head with primary open-angle glaucoma.  J Glaucoma
1997, 6(5):303-313.
20. Eng LF, Ghirnikar RS, Lee YL: Glial fibrillary acidic protein:
GFAP-thirty-one years (1969–2000).  Neurochem Res 2000,
25(9–10):1439-1451.
21. Liu N, Neufeld AH: Nitric oxide synthase-2 in human optic
nerve head astrocytes induced by elevated hydrostatic pres-
sure.  Arch Ophthalmol 2001, 119:240-245.
22. Tezel G, Wax MB: Increased production of tumor necrosis fac-
tor-alpha by glial cells exposed to simulated ischemia or ele-
vated hydrostatic pressure induces apoptosis in cocultured
retinal ganglion cells.  J Neurosci 2000, 20(23):8693-8700.
23. Yang P, Agapova O, Parker A, Shannon W, Pecen P, Duncan J, Salva-
dor-Silva M, Hernandez MR: DNA microarray analysis of gene
expression in human optic nerve head astrocytes in response
to hydrostatic pressure.  Physiol Genomics 2004, 17(2):157-169.
24. Johnson EC, Jia L, Cepurna WO, Doser TA, Morrison JC: Global
Changes in Optic Nerve Head Gene Expression after Expo-
sure to Elevated Intraocular Pressure in a Rat Glaucoma
Model.  Investigative Ophthalmology & Visual Science 2007,
48(7):3161-3177.
25. Steele MR, Inman DM, Calkins DJ, Horner PJ, Vetter ML: Microarray
Analysis of Retinal Gene Expression in the DBA/2J Model of
Glaucoma.  Investigative Ophthalmology & Visual Science 2006,
47(3):977-985.
26. Miyahara T, Kikuchi T, Akimoto M, Kurokawa T, Shibuki H,
Yoshimura N: Gene microarray analysis of experimental glau-
comatous retina from cynomologous monkey.  Invest Ophthal-
mol Vis Sci 2003, 44(10):4347-4356.
27. Ahmed F, Brown KM, Stephan DA, Morrison JC, Johnson EC,
Tomarev SI: Microarray analysis of changes in mRNA levels in
the rat retina after experimental elevation of intraocular
pressure.  Invest Ophthalmol Vis Sci 2004, 45(4):1247-1258.
28. Bachoo RM, Kim RS, Ligon KL, Maher EA, Brennan C, Billings N, Chan
S, Li C, Rowitch DH, Wong WH: Molecular diversity of astro-
cytes with implications for neurological disorders.  Proc Natl
Acad Sci USA 2004, 101(22):8384-8389.
29. Calabria AR, Shusta EV: A genomic comparison of in vivo and in
vitro brain microvascular endothelial cells.  Journal of Cerebral
Blood Flow & Metabolism 2007.
30. Pass MB, Borregaard N, Cowland JB: Derangement of transcrip-
tion factor profiles during in vitro differentiation of HL60 and
NB4 cells.  Leuk Res 2006, 31(6):827.
31. Boothe RG, Dobson V, Teller DY: Postnatal Development of
Vision in Human and Nonhuman Primates.  Annual Review of
Neuroscience 1985, 8(1):495-545.
32. Harwerth RS, Smith EL: The rhesus monkey as a model for nor-
mal vision of humans.  Am J Optom Physiol Opt 1985, 62:633-641.
33. Fujita Y, Imagawa T, Uehara M: Comparative study of the lamina
cribrosa and the pial septa in the vertebrate optic nerve and
their relationship to the myelinated axons.  Tissue Cell 2000,
32(4):293-301.
34. Johansson JO: The lamina cribrosa in the eyes of rats, ham-
sters, gerbils and guinea pigs.  Acta Anat (Basel) 1987,
128(1):55-62.
35. Harwerth RS, Carter-Dawson L, Shen F, Smith EL, Crawford MLJ:
Ganglion Cell Losses Underlying Visual Field Defects from
Experimental Glaucoma.  Investigative Ophthalmology & Visual Sci-
ence 1999, 40(10):2242-2250.
36. Edgar R: Gene Expression Omnibus: NCBI gene expression
and hybridization array data repository.  Nucleic Acids Research
2002, 30(1):207-210.
37. Gaasterland D, Kupfer C: Reports: Experimental Glaucoma in
the Rhesus Monkey.  Investigative Ophthalmology & Visual Science
1974, 13(6):455-457.
38. Quigley HA, Hohman RM: Laser energy levels for trabecular
meshwork damage in the primate eye.  Investigative Ophthalmol-
ogy & Visual Science 1983, 24(9):1305-1307.
39. Kaufman PL, Davis GE: " Minified" Goldmann applanating prism
for tonometry in monkeys and humans.  Archives of Ophthalmol-
ogy 1980, 98(3):542-546.
40. Bagga H, Greenfield DS, Feuer W, Knighton RW: Scanning laser
polarimetry with variable corneal compensation and optical
coherence tomography in normal and glaucomatous eyes.
Am J Ophthalmol 2003, 135(4):521-529.
41. Da Pozzo S, Iacono P, Marchesan R, Fantin A, Ravalico G: Scanning
laser polarimetry with variable corneal compensation and
detection of glaucomatous optic neuropathy.  Graefes Arch Clin
Exp Ophthalmol 2005, 243(8):774.
42. Reus NJ, Lemij HG: Diagnostic accuracy of the GDx VCC for
glaucoma.  Ophthalmology 2004, 111(10):1860-1865.
43. Weinreb RN, Bowd C, Greenfield DS, Zangwill LM: Measurement
of the magnitude and axis of corneal polarization with scan-
ning laser polarimetry.  Arch Ophthalmol 2002, 120(7):901-906.
44. Schmidt JF, Agapova OA, Yang P, Kaufman PL, Hernandez MR:
Expression of ephrinB1 and its receptor in glaucomatous
optic neuropathy.  British Journal of Ophthalmology 2007,
91(9):1219.
45. Pena JD, Agapova O, Gabelt BT, Levin LA, Lucarelli MJ, Kaufman PL,
Hernandez MR: Increased elastin expression in astrocytes of
the lamina cribrosa in response to elevated intraocular pres-
sure.  Invest Ophthalmol Vis Sci 2001, 42(10):2303-2314.
46. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE,
Myers RM, Speed TP, Akil H: Evolving gene/transcript defini-
tions significantly alter the interpretation of GeneChip data.
Nucleic Acids Research 2005, 33(20):e175.
47. Huber W, Gentleman R: matchprobes: a Bioconductor package
for the sequence-matching of microarray probe elements.
Volume 20. Oxford Univ Press; 2004:1651-1652. 
48. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ,
Scherf U, Speed TP: Exploration, normalization, and summa-
ries of high density oligonucleotide array probe level data.
Biostatistics 2003, 4:249-264.
4 9 . G a u t i e r  L ,  C o p e  L ,  B o l s t a d  B M ,  I r i z a r r y  R A :  affy – analysis of
Affymetrix GeneChip data at the probe level.  Bioinformatics
2004, 20(3):307-315.
50. Wang Z, Lewis MG, Nau ME, Arnold A, Vahey MT: Identification
and utilization of inter-species conserved (ISC) probesets on
Affymetrix human GeneChip platforms for the optimization
of the assessment of expression patterns in non human pri-
mate (NHP) samples.  BMC Bioinformatics 2004, 5(1):165.BMC Neuroscience 2008, 9:93 http://www.biomedcentral.com/1471-2202/9/93
Page 20 of 21
(page number not for citation purposes)
51. Breitling R, Armengaud P, Amtmann A, Herzyk P: Rank products: a
simple, yet powerful, new method to detect differentially
regulated genes in replicated microarray experiments.  FEBS
Lett 2004, 573(1):83-92.
52. Tusher VG, Tibshirani R, Chu G: Significance analysis of micro-
arrays applied to the ionizing radiation response.  Proceedings
of the National Academy of Sciences 2001, 98(9):5116-5121.
53. Benjamini Y, Hochberg Y: Controlling the False Discovery Rate:
A Practical and Powerful Approach to Multiple Testing.  Jour-
nal of the Royal Statistical Society Series B (Methodological) 1995,
57(1):289-300.
54. Efron B, Tibshirani R: Empirical bayes methods and false discov-
ery rates for microarrays.  Genet Epidemiol 2002, 23(1):70-86.
55. Stead JDH, Neal C, Meng F, Wang Y, Evans S, Vazquez DM, Watson
SJ, Akil H: Transcriptional Profiling of the Developing Rat
Brain Reveals That the Most Dramatic Regional Differentia-
tion in Gene Expression Occurs Postpartum.  Journal of Neuro-
science 2006, 26(1):345-353.
56. Affymetrix:  Statistical Algorithms Description Document.
Technical paper 2002.
57. Liu WM, Mei R, Di X, Ryder TB, Hubbell E, Dee S, Webster TA, Har-
rington CA, Ho MH, Baid J: Analysis of high density expression
microarrays with signed-rank call algorithms.  Bioinformatics
2002, 18(12):1593-1599.
58. Farkas RH, Qian J, Goldberg JL, Quigley HA, Zack DJ: Gene Expres-
sion Profiling of Purified Rat Retinal Ganglion Cells.  Investiga-
tive Ophthalmology and Visual Science 2004, 45:2503-2513.
59. Ivanov D, Dvoriantchikova G, Nathanson L, McKinnon SJ,
Shestopalov VI: Microarray analysis of gene expression in adult
retinal ganglion cells.  FEBS Lett 2006, 580(1):331-335.
60. Weinreb RN, Bowd C, Zangwill LM: Scanning Laser Polarimetry
in Monkey Eyes using Variable Corneal Polarization Com-
pensation.  Journal of Glaucoma 2002, 11(5):378.
61. Quigley HA, Addicks EM, Green WR: Optic nerve damage in
human glaucoma. III. Quantitative correlation of nerve fiber
loss and visual field defect in glaucoma, ischemic neuropa-
thy, papilledema, and toxic neuropathy.  Arch Ophthalmol 1982,
100(1):135-146.
62. Calvert PD, Strissel KJ, Schiesser WE, Pugh EN, Arshavsky VY: Light-
driven translocation of signaling proteins in vertebrate pho-
toreceptors.  Trends Cell Biol 2006, 16(11):560-568.
63. Chen J, Yoshida T, Nakano K, Bitensky MW: Subcellular localiza-
tion of phosducin in rod photoreceptors.  Vis Neurosci 2005,
22(1):19-25.
64. Anderson MG, Smith RS, Hawes NL, Zabaleta A, Chang B, Wiggs JL,
John SWM: Mutations in genes encoding melanosomal pro-
teins cause pigmentary glaucoma in DBA/2 J mice.  Nature
Genetics 2002, 30(1):81-85.
65. Chang B, Smith RS, Hawes NL, Anderson MG, Zabaleta A, Savinova
O, Roderick TH, Heckenlively JR, Davisson MT, John SWM: Inter-
acting loci cause severe iris atrophy and glaucoma in DBA/2J
mice.  Nature Genetics 1999, 21:405-409.
66. Carmichael ST, Archibeque I, Luke L, Nolan T, Momiy J, Li S:
Growth-associated gene expression after stroke: evidence
for a growth-promoting region in peri-infarct cortex.  Exp
Neurol 2005, 193(2):291-311.
67. Gervasi C, Thyagarajan A, Szaro BG: Increased expression of mul-
tiple neurofilament mRNAs during regeneration of verte-
brate central nervous system axons.  J Comp Neurol 2003,
461(2):262-275.
68. Meunier L, Usherwood YK, Chung KT, Hendershot LM: A subset of
chaperones and folding enzymes form multiprotein com-
plexes in endoplasmic reticulum to bind nascent proteins.
Mol Biol Cell 2002, 13(12):4456-4469.
69. Tezel G, Wax MB: The immune system and glaucoma.  Current
Opinion in Ophthalmology 2004, 15(2):80.
70. Anderson DR, Hendrickson A: Effect of intraocular pressure on
rapid axoplasmic transport in monkey optic nerve.  Invest Oph-
thalmol 1974, 13(10):771-783.
71. Libby RT, Li Y, Savinova OV, Barter J, Smith RS, Nickells RW, John
SWM: Susceptibility to neurodegeneration in a glaucoma is
modified by bax gene dosage.  PLoS Genet 2005, 1(1):17-26.
72. Quigley HA, Addicks EM, Green WR, Maumenee AE: Optic nerve
damage in human glaucoma. II. The site of injury and suscep-
tibility to damage.  Archives of Ophthalmology 1981, 99(4):635-649.
73. Quigley HA, Hohman RM, Addicks EM, Massof RW, Green WR:
Morphologic changes in the lamina cribrosa correlated with
neural loss in open-angle glaucoma.  Am J Ophthalmol 1983,
95(5):673-691.
74. Carter SL, Eklund AC, Mecham BH, Kohane IS, Szallasi Z: Redefini-
tion of Affymetrix probe sets by sequence overlap with
cDNA microarray probes reduces cross-platform inconsist-
encies in cancer-associated gene expression measurements.
BMC Bioinformatics 2005, 6(1):107.
75. Gautier L, Moller M, Friis-Hansen L, Knudsen S: Alternative map-
ping of probes to genes for Affymetrix chips.  BMC Bioinformat-
ics 2004, 5(1):111.
76. Harbig J, Sprinkle R, Enkemann SA: A sequence-based identifica-
tion of the genes detected by probesets on the Affymetrix
U133 plus 2.0 array.  Nucleic Acids Res 2005, 33(3):e31.
77. Mecham BH, Klus GT, Strovel J, Augustus M, Byrne D, Bozso P, Wet-
more DZ, Mariani TJ, Kohane IS, Szallasi Z: Sequence-matched
probes produce increased cross-platform consistency and
more reproducible biological results in microarray-based
gene expression measurements.  Nucleic Acids Res 2004,
32(9):e74.
78. Mecham BH, Wetmore DZ, Szallasi Z, Sadovsky Y, Kohane I, Mariani
TJ: Increased measurement accuracy for sequence-verified
microarray probes.  Physiol Genomics 2004, 18:308-315.
79. Ogawa T, Nikawa T, Furochi H, Kosyoji M, Hirasaka K, Suzue N,
Sairyo K, Nakano S, Yamaoka T, Itakura M: Osteoactivin upregu-
lates expression of MMP-3 and MMP-9 in fibroblasts infil-
trated into denervated skeletal muscle in mice.  American
Journal of Physiology-Cell Physiology 2005, 289(3):697-707.
80. Rich JN, Shi Q, Hjelmeland M, Cummings TJ, Kuan CT, Bigner DD,
Counter CM, Wang XF: Bone-related Genes Expressed in
Advanced Malignancies Induce Invasion and Metastasis in a
Genetically Defined Human Cancer Model.  Journal of Biological
Chemistry 2003, 278(18):15951-15957.
81. Agapova OA, Kaufman PL, Lucarelli MJ, Gabelt BT, Hernandez MR:
Differential expression of matrix metalloproteinases in mon-
key eyes with experimental glaucoma or optic nerve
transection.  Brain Res 2003, 967:1-2.
82. Agapova OA, Ricard CS, Salvador-Silva M, Hernandez MR: Expres-
sion of matrix metalloproteinases and tissue inhibitors of
metalloproteinases in human optic nerve head astrocytes.
Glia 2001, 33(3):205-216.
83. Aloisi F, Ria F, Adorini L: Regulation of T-cell responses by CNS
antigen-presenting cells: different roles for microglia and
astrocytes.  Immunol Today 2000, 21(3):141-147.
84. Aloisi F, Serafini B, Adorini L: Glia-T cell dialogue.  J Neuroimmunol
2000, 107(2):111-117.
85. Becher B, Prat A, Antel JP: Brain-immune connection: immuno-
regulatory properties of CNS-resident cells.  Glia 2000,
29(4):293-304.
86. Tezel G, Wax MB: The immune system and glaucoma.  Curr
Opin Ophthalmol 2004, 15(2):80-84.
87. Harvey AR, Hu Y, Leaver SG, Mellough CB, Park K, Verhaagen J, Plant
GW, Cui Q: Gene therapy and transplantation in CNS repair:
The visual system.  Prog Retin Eye Res 2006, 25(5):449-489.
88. Verma P, Chierzi S, Codd AM, Campbell DS, Meyer RL, Holt CE,
Fawcett JW: Axonal protein synthesis and degradation are
necessary for efficient growth cone regeneration.  J Neurosci
2005, 25(2):331-342.
89. Erturk A, Hellal F, Enes J, Bradke F: Disorganized Microtubules
Underlie the Formation of Retraction Bulbs and the Failure
of Axonal Regeneration.  Journal of Neuroscience 2007,
27(34):9169.
90. Yu FX, Johnston PA, Sudhof TC, Yin HL: gCap 39, a calcium ion-
and polyphosphoinositide-regulated actin capping protein.
Science 1990, 250(4986):1413.
91. Bahassi EM, Karyala S, Tomlinson CR, Sartor MA, Medvedovic M,
Hennigan RF: Critical regulation of genes for tumor cell migra-
tion by AP-1.  Clinical and Experimental Metastasis 2004,
21(4):293-304.
92. De Corte V, Van Impe K, Bruyneel E, Boucherie C, Mareel M,
Vandekerckhove J, Gettemans J: Increased importin-β-depend-
ent nuclear import of the actin modulating protein CapG
promotes cell invasion.  Journal of Cell Science 2004,
117(22):5283-5292.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Neuroscience 2008, 9:93 http://www.biomedcentral.com/1471-2202/9/93
Page 21 of 21
(page number not for citation purposes)
93. Song F, Wisithphrom K, Zhou J, Windsor LJ: Matrix metallopro-
teinase dependent and independent collagen degradation.
Front Biosci 2006, 11:3100-3120.
94. Yan X, Tezel G, Wax MB, Edward DP: Matrix metalloproteinases
and tumor necrosis factor alpha in glaucomatous optic nerve
head.  Arch Ophthalmol 2000, 118(5):666.
95. Ripoll VM, Irvine KM, Ravasi T, Sweet MJ, Hume DA: Gpnmb Is
Induced in Macrophages by IFN-{gamma} and Lipopolysac-
charide and Acts as a Feedback Regulator of Proinflamma-
tory Responses.  The Journal of Immunology 2007, 178(10):6557.
96. Shikano S, Bonkobara M, Zukas PK, Ariizumi K: Molecular Cloning
of a Dendritic Cell-associated Transmembrane Protein, DC-
HIL, That Promotes RGD-dependent Adhesion of Endothe-
lial Cells through Recognition of Heparan Sulfate Proteogly-
cans.  Journal of Biological Chemistry 2001, 276(11):8125-8134.
97. Haralanova-Ilieva B, Ramadori G, Armbrust T: Expression of oste-
oactivin in rat and human liver and isolated rat liver cells.  J
Hepatol 2005, 42(4):565-572.
98. Onaga M, Ido A, Hasuike S, Uto H, Moriuchi A, Nagata K, Hori T,
Hayashi K, Tsubouchi H: Osteoactivin expressed during cirrho-
sis development in rats fed a choline-deficient.  L-amino acid-
defined diet, accelerates motility of hepatoma cells J Hepatol 2003,
39(779):85.
99. Weterman MA, Ajubi N, van Dinter IM, Degen WG, van Muijen GN,
Ruitter DJ, Bloemers HP: nmb, a novel gene, is expressed in low-
metastatic human melanoma cell lines and xenografts.  Int J
Cancer 1995, 60(1):73-81.
100. Nieto-Sampedro M, Gomez-Pinilla F, Knauer DJ, Broderick JT: Epi-
dermal growth factor receptor immunoreactivity in rat
brain astrocytes. Response to injury.  Neurosci Lett 1988,
91(3):276-282.
101. Liu B, Chen H, Johns TG, Neufeld AH: Epidermal Growth Factor
Receptor Activation: An Upstream Signal for Transition of
Quiescent Astrocytes into Reactive Astrocytes after Neural
Injury.  Journal of Neuroscience 2006, 26(28):7532.
102. John SW, Smith RS, Savinova OV, Hawes NL, Chang B, Turnbull D,
Davisson M, Roderick TH, Heckenlively JR: Essential iris atrophy,
pigment dispersion, and glaucoma in DBA/2J mice.  Invest Oph-
thalmol Vis Sci 1998, 39(6):951-962.
103. Howell GR, Libby RT, Marchant JK, Wilson LA, Cosma IM, Smith RS,
Anderson MG, John SWM: Absence of glaucoma in DBA/2 J
mice homozygous for wild-type versions of Gpnmb and Tyrp
1.  BMC Genetics 2007, 8(1):45.
104. Mo JS, Anderson MG, Gregory M, Smith RS, Savinova OV, Serreze
DV, Ksander BR, Streilein JW, John SWM: By Altering Ocular
Immune Privilege, Bone Marrow-derived Cells Pathogeni-
cally Contribute to DBA/2J Pigmentary Glaucoma.  Journal of
Experimental Medicine 2003, 197(10):1335-1344.
105. Zhou X, Li F, Kong L, Tomita H, Li C, Cao W: Involvement of
Inflammation, Degradation, and Apoptosis in a Mouse Model
of Glaucoma.  Journal of Biological Chemistry 2005,
280(35):31240-31248.